Regeneron Pharmaceuticals faces significant legal challenges after investors accused the company of misleading them about drug pricing practices and reimbursement risks, particularly regarding how the pharmaceutical giant handled pricing schemes for its blockbuster drug Eylea. The company’s stock dropped more than 9% on October 31, 2024, following earnings announcements that revealed previously undisclosed information about credit card fee payments and price concessions, wiping out approximately $9 billion in market capitalization and triggering multiple lawsuits.
These legal actions center on allegations that Regeneron made false and misleading statements about how it reported its drug prices to Medicare, the federal health insurance program that has paid more than $25 billion for Eylea since 2012. The litigation unfolds on two major fronts: a securities class action lawsuit where investors claim they were misled about the company’s financial health, and a Department of Justice complaint alleging that Regeneron fraudulently inflated Medicare reimbursement rates by submitting inaccurate pricing reports. At the heart of both cases lies a complex scheme involving credit card processing fees that Regeneron allegedly paid to specialty drug distributors on condition they wouldn’t pass those fees along to customers—effectively subsidizing prices while failing to disclose these payments as required price concessions.
Table of Contents
- How Regeneron Allegedly Misled Investors About Pricing and Reimbursement Practices
- The DOJ’s False Claims Act Complaint Against Regeneron
- Eylea and Its Massive Medicare Market Significance
- What Investors and Regulators Allege Happened with Credit Card Fees
- The Broader Context of Drug Pricing Manipulation and Reimbursement Schemes
- Impact on Current Drug Pricing Oversight and Future Compliance
- Current Status and What Happens Next in These Cases
- Conclusion
How Regeneron Allegedly Misled Investors About Pricing and Reimbursement Practices
The securities class action lawsuit, Radtke v. Regeneron Pharmaceuticals, Inc. (No. 25-cv-00145, S.D.N.Y.), targets a narrow but crucial window of time. Investors who purchased Regeneron stock between November 2, 2023 and October 30, 2024—the class period—claim the company made false and misleading statements regarding credit card fee payments to distributors and price concessions on Eylea.
The lawsuit suggests that Regeneron’s disclosure failures meant investors didn’t understand the true financial risks the company faced from these pricing practices and potential regulatory consequences. What makes this case particularly significant is the magnitude of the stock price movement that triggered investor scrutiny. When information about these pricing arrangements became public knowledge around the October 31, 2024 earnings announcement, the market reacted swiftly and harshly, suggesting investors viewed the previously undisclosed information as material to their investment decisions. This dramatic $9 billion market capitalization loss raises a critical question: if Regeneron knew about these fee arrangements and their regulatory implications, why didn’t it disclose them to shareholders earlier? The lead plaintiff deadline for the securities case was March 10, 2025, meaning investors who purchased stock during the class period and want to participate in potential recoveries needed to file claims by that date. However, it’s important to note that no verdict or settlement has been reached in this case as of mid-2026; the litigation remains pending and may take years to resolve.
The DOJ’s False Claims Act Complaint Against Regeneron
In April 2024, the Department of Justice filed a complaint against Regeneron in U.S. District Court, District of Massachusetts, alleging that the company fraudulently inflated Medicare reimbursement rates for Eylea by submitting false Average Sales Price (ASP) reports. This is a civil False Claims Act case, meaning the government alleges Regeneron knowingly submitted false claims to Medicare for reimbursement amounts. The specific allegation centers on Regeneron’s failure to report credit card processing fee reimbursements as price concessions, which are legally required to be factored into ASP calculations.
According to the DOJ complaint, Regeneron paid “hundreds of millions of dollars” in credit card fee reimbursements to specialty drug distributors between 2012 and mid-2021, with reimbursements to just one distributor exceeding $250 million during that period. The scheme reportedly worked as follows: Regeneron would reimburse specialty distributors for credit card processing fees they incurred when customers paid for Eylea with credit cards, but it did so on the condition that the distributors would not pass these fees along to customers. This arrangement effectively subsidized prices while keeping the reimbursements hidden from Medicare’s pricing calculations. A critical limitation in understanding the DOJ case is that it relies on technical healthcare law regarding ASP reporting requirements—complex regulations that most patients and many investors don’t fully understand. The difference between a “price concession” and a “cost reimbursement” might seem semantic to outsiders, but to Medicare and pricing authorities, the distinction determines whether a company has complied with federal law.
Eylea and Its Massive Medicare Market Significance
Eylea is Regeneron’s most commercially important drug, first approved by the FDA in late 2011 for treating wet age-related macular degeneration (AMD), a leading cause of vision loss in elderly Americans. The drug’s market success has been extraordinary: between 2012 and 2023 alone, Medicare paid more than $25 billion for Eylea treatments, making it one of the highest-reimbursed drugs under the Medicare program. For context, this means that for every elderly American who received Eylea injections during this period, Medicare’s costs for the drug alone represented a substantial portion of the nation’s healthcare budget.
Eylea’s dominance in the wet AMD treatment market makes the pricing allegations particularly significant. When Medicare overpays for a drug due to false price reporting, the overpayment affects not just one patient or one healthcare system, but seniors across the entire nation covered by Medicare. The cumulative impact of Regeneron’s pricing practices, if proven, could affect millions of beneficiaries and billions in taxpayer dollars. Additionally, when one pharmaceutical company successfully inflates Medicare prices through such schemes, it can create competitive pressure on other manufacturers to adopt similar tactics.
What Investors and Regulators Allege Happened with Credit Card Fees
The core allegation involves a practice that, on its surface, might seem like routine business administration: reimbursing distributors for the cost of processing credit card payments. In the pharmaceutical distribution system, specialty distributors often handle high-cost medications like Eylea and may bear the costs of credit card processing fees when customers pay with plastic rather than cash. Regeneron’s practice of reimbursing these fees might initially appear reasonable—after all, if a distributor must absorb a cost, the drug manufacturer could simply reimburse it. However, Medicare’s pricing regulations require that any financial arrangement reducing the effective price customers pay must be reported as a “price concession” and factored into ASP calculations.
By reimbursing distributors for credit card fees on the condition that these fees wouldn’t be passed to customers, Regeneron effectively reduced the out-of-pocket cost to patients while simultaneously reducing the reported average selling price—except the reductions allegedly weren’t reported to Medicare. This created an artificial situation where Medicare paid prices that didn’t reflect the actual dollars the company received from distributors and patients combined. The comparison that illustrates this best: imagine if a car manufacturer sold cars for $50,000 but secretly paid $5,000 back to dealerships for “administrative costs,” then reported the average selling price as $50,000 rather than $45,000 to a government program determining reimbursement rates. That’s essentially what the allegations suggest Regeneron did with Eylea pricing and Medicare.
The Broader Context of Drug Pricing Manipulation and Reimbursement Schemes
These allegations don’t occur in a vacuum—they reflect ongoing tensions between pharmaceutical companies’ profit incentives and federal healthcare programs’ interest in paying reasonable prices. Over the past decade, the Medicare program has faced escalating costs from specialty drugs like Eylea, leading to increased scrutiny of how drug manufacturers report their prices.
The ASP reporting system, while designed to tie Medicare reimbursement to actual market prices, has proven vulnerable to manipulation when manufacturers and distributors coordinate their financial arrangements carefully. One important limitation to understand: proving fraud requires demonstrating that Regeneron knowingly submitted false information with intent to deceive. The company has stated it believes the allegations are “without merit,” characterizing the fee payments as “lawful reimbursement of costs incurred by our specialty distributors.” This defense raises a legitimate legal question that courts will need to resolve: did Regeneron genuinely believe these reimbursements didn’t constitute reportable price concessions under Medicare rules, or did the company know it was required to report them but failed to do so? The answer to that question will substantially impact the outcome of both the DOJ case and the securities litigation.
Impact on Current Drug Pricing Oversight and Future Compliance
These cases have already influenced how regulators scrutinize pharmaceutical pricing practices. The DOJ’s willingness to pursue a False Claims Act case against Regeneron signals that the federal government views creative fee arrangements as fertile ground for enforcement actions. For other pharmaceutical manufacturers, the Regeneron cases serve as a warning that pricing arrangements involving distributors, even if they appear to be cost reimbursements, may trigger regulatory investigation if they reduce the effective price without proper ASP reporting.
The securities litigation adds another layer of enforcement pressure: companies must now consider whether complex pricing arrangements should be disclosed to investors as material risks. If courts determine that Regeneron’s failure to disclose these arrangements to shareholders constituted securities fraud, other pharmaceutical manufacturers will face pressure to enhance their disclosure practices or risk similar investor litigation. This creates a compliance ecosystem where both regulators (through the DOJ) and private parties (through securities lawsuits) can hold companies accountable for pricing practices.
Current Status and What Happens Next in These Cases
As of mid-2026, both cases remain pending with no settlement or verdict reached. The securities class action continues through discovery, where both Regeneron and the plaintiffs exchange documents and evidence. The DOJ case similarly continues its litigation course, though specific procedural status updates are limited in public records.
For investors who purchased Regeneron stock during the class period and didn’t file claims by the March 10, 2025 lead plaintiff deadline, participation in any eventual recovery would not be available. The timeline for resolution in both cases likely extends years into the future, as pharmaceutical litigation typically involves extensive discovery and legal briefing before trials or settlements occur. The financial stakes are substantial: if the DOJ prevails on its False Claims Act allegations, Regeneron could face significant civil penalties plus potential repayment of the difference between what Medicare was charged and what it should have been charged based on proper ASP reporting. The securities settlement, if reached, would be funded from Regeneron’s insurance coverage and potentially shareholder assets, depending on the lawsuit’s outcome.
Conclusion
The Regeneron class action litigation represents a watershed moment in pharmaceutical pricing oversight, demonstrating that regulators and private investors increasingly scrutinize complex fee arrangements between drug manufacturers and distributors. The allegations that Regeneron misled investors about drug pricing risks while simultaneously submitting false price information to Medicare highlight the intersection of securities law, healthcare fraud law, and pharmaceutical market regulation.
Whether courts ultimately find in favor of plaintiffs or determine that Regeneron’s practices were lawful, these cases have already reshaped how the industry thinks about pricing disclosures. If you purchased Regeneron stock between November 2, 2023 and October 30, 2024 and have questions about participating in securities litigation or whether you may have rights in these cases, consulting with a securities attorney can help clarify your situation. Similarly, if you’re a healthcare provider or patient organization concerned about fair drug pricing, monitoring the outcomes of these cases will be important, as they may influence future Medicare pricing policies and pharmaceutical industry compliance practices.